Ipsen presents new data on IPN10200, enabling initiation of Phase III

French drugmaker Ipsen (Euronext: IPN) has revealed the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically-significant improvement in response at Week 4 versus placebo (primary endpoint).

Ipsen noted that a longer duration of effect was also observed with a substantial majority of patients experiencing a clinically significant response at Week 24 compared with placebo and Dysport, defined as a score of “none” or “mild”. IPN10200 continued to show a greater response in line severity versus Dysport at Week 36. In this trial Dysport was shown to perform consistently with its profile.

The company said that data will be shared in a scientific conference in the first half of 2026 and activities for Ipsen’s global Phase III program in glabellar lines have been initiated.